2020 Plenary Keynote Speakers
Stanley Riddell, MD, Scientific Director, Clinical Research, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine
Roy D. Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharpe & Dohme
Additional 2020 Featured Speakers
Edith Borcoman, MD, Medical Oncologist, Institut Curie, Paris
Renier Brentjens, MD, PhD, Director, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center; Professor, Pharmacology, Weill Cornell Graduate School of Medical Sciences
Sara Colombetti, PhD, Global Head of Oncology Discovery Pharmacology, Pharma Research and Early Development (pRED), Roche Innovation Center Zurich
George Coukos, Full Professor and Director, Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL); Director, Lausanne Branch, Ludwig Institute of Cancer Research Chief, Service of Immuno-Oncology, CHUV
Lindy Durrant, PhD, Professor of Cancer immunotherapy, University of Nottingham; CSO, Scancell Ltd
Gordon J. Freeman, PhD, Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
Maria Karasarides, PhD, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals
Roland Kontermann, PhD, Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart
Jeanette Leusen, PhD, Associate Professor and Head Immunotherapy Group, Translational Immunology, University Medical Centre Utrecht
Wouter Scheper, PhD, Senior Postdoc, Molecular Oncology and Immunology, Netherlands Cancer Institute
Karoline Schjetne, PhD, Vice President Scientific Affairs, Vaccibody
Hans van der Vliet, MD, PhD, CSO, LAVA Therapeutics; Medical Oncologist, Amsterdam UMC
ABOUT THE EVENT
Cambridge Healthtech Institute’s Fifth Immuno-Oncology Summit Europe returns to the heart of London’s Canary Wharf for 3 days of cutting edge science and discussion. Through six conference tracks, delegates will hear from the research teams at the forefront of the rapidly developing field of cancer biotherapeutics.
